Skip to main content
Skip to main content
ImmunoPrecise Antibodies Ltd. ImmunoPrecise Antibodies Ltd.
  • Overview
    • News
      • News Releases
      • In the Media
    • Events & Presentations
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts

Executive Management

  • Overview
    • News
      • News Releases
      • In the Media
    • Events & Presentations
    • Stock Info
      • Stock Quote
      • Stock Chart
      • Historical Stock Quote
      • Investment Calculator
      • Dividend History
      • Analyst Coverage
    • Financials
      • Quarterly Results
      • Annual Reports
      • SEC Filings
    • Governance
      • Governance Documents
      • Executive Management
      • Board of Directors
      • Committee Composition
    • Resources
      • Information Request Form
      • Investor Email Alerts
      • Investor Contacts

Executive Management Carousel

Dr. Jennifer Bath, Chief Executive Officer and President

Jennifer Bath is the CEO and President of ImmunoPrecise Antibodies. She obtained a Ph.D. in Cellular and Molecular Biology, specializing in immunology and biochemistry, with a focus on discovering and validating biologics for the prevention and treatment of neglected tropical diseases. Dr. Bath held a tenured position as an Associate Professor of Cellular and Molecular Biology, while concurrently serving as the Founder and Executive Director of the Concordia Global Vaccine Institute. She also served many years as a strategic growth and business operations advisor for global pharma, biotech, and government.

Dr. Bath has held executive roles in both biotechnology and contract research organizations, with her most recent post on the executive team at Aldevron, LLC. Here, she headed the global sales and client relations teams, and defined business strategies by applying knowledge based on the science, technology and market. In addition, she served as a key technical specialist, converting challenges for pharmaceutical and biotechnology clients into operational initiatives.

Joseph Scheffler, Interim Chief Financial Officer

Joseph Scheffler is the interim CFO of IPA. He has a BS in Accounting and MBA in Finance from Loyola University of Chicago. His career includes over 20 years as a Corporate Financial Consultant across several different industries of various size and complexity.

He previously worked for Ernst & Young and has held executive positions of CFO, Vice President of Finance and Corporate Treasurer. His background blends publicly traded company operations with successful startup ventures and emerging businesses.  As an executive and consultant, he has led and successfully managed finance and accounting teams.

 

Ingrid Brands MD PHD, Chief Innovation and Strategy Officer

Ingrid Brands is the Chief Innovation and Strategy Officer of ImmunoPrecise Antibodies, with over two decades in management and senior research roles. She has made significant contributions to the field of medicine and neurorehabilitation. 

Throughout her career, Dr. Brands has pioneered innovative approaches in neuropsychological rehabilitation, enhancing the care provided to patients with acquired brain injuries. She has held respected research positions at esteemed institutions such as Libra Revalidatie & Audiologie and the Department of Rehabilitation at Erasmus University. 

Dr. Brands holds a Ph.D. in neurorehabilitation from the University of Maastricht and graduated with distinction from the University of Leuven, specializing in Physical Medicine and Rehabilitation (PM&R). Her commitment to advancing the field is evident in her academic achievements and active involvement in professional committees. 

Under Dr. Brands' leadership, IPA and its subsidiary BioStrand continue to evolve, utilizing cutting-edge research and technology to drive advancements in genetic research. Her dedication to innovation and patient care serves as the driving force behind IPA's achievements. 

Dirk Van Hyfte MD PHD, Chief Technology Officer

Dirk Van Hyfte is the Chief Technology Officer of ImmunoPrecise Antibodies. With a degree in Medicine and specialization as a Psychiatrist from the prestigious University of Leuven in Belgium, Dirk's expertise extends beyond the realms of technology and business.

As a serial entrepreneur, Dirk has already made significant contributions to the field, with several of his groundbreaking ideas earning him patents. Notably, his remarkable achievement, iKnow, caught the attention of IT provider InterSystems, leading to its acquisition in 2010.

In addition to his entrepreneurial ventures, Dirk serves as a Bio-Medical Advisor, seamlessly blending his medical, AI-analytics, technological, and business acumen. He leverages his profound understanding of medical artificial intelligence, having obtained a PhD in the field from Nijmegen University in the Netherlands.

Dirk’s leadership brings a unique combination of healthcare systems knowledge and AI-driven strategy, positioning IPA at the forefront of industry innovation.

Portrait

Dr. Ilse Roodink, Chief Scientific Officer

Dr. Ilse Roodink serves as Chief Scientific Officer (CSO) of ImmunoPrecise Antibodies, supporting the company’s global research and development teams. Prior to her appointment as CSO, she held different scientific positions at the Company’s Dutch facility in Oss from 2013 until 2021. In her last role as Scientific Director of ImmunoPrecise Europe, Dr. Roodink was overseeing contract research project execution and management and actively involved in the integration of innovative technologies supporting antibody characterization and engineering. Following its establishment in 2019, Dr. Roodink has served as Chairwoman of Talem Therapeutics’ Scientific Advisory Committee, leading the development of Talem’s pipeline assets.

Dr. Roodink graduated from Radboud University of Nijmegen, the Netherlands with a Master’s degree in Biomedical Health Sciences and a Ph.D. in Medical Sciences. Her work, resulting in several peer-reviewed publications, focused on platform development to facilitate the discovery of antibodies specifically recognizing native tumor targets.

Frédéric Chabot, Head of Corporate Development

Frédéric Chabot is the Head of Corporate Development at ImmunoPrecise Antibodies (IPA), focusing on M&A, strategic partnerships, and corporate initiatives. He began working with IPA in 2017, contributing in various roles before assuming his current position. With over 26 years of experience in finance and corporate strategy, he navigates biotech investments and market expansion.

Previously, he served as an International Liaison at Contact Financial, an advisory firm specializing in capital raising and investor relations for TSX and TSX-V listed companies. Over nine years, he worked on investor awareness programs and fundraising initiatives, supporting startups and early-stage companies.

Kari Graber, VP of Commercial Services

Kari Graber serves as the Vice President of Commercial Services for ImmunoPrecise Antibodies, and is responsible for the overall leadership and implementation of the Project Management program throughout ImmunoPrecise’s global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining ImmunoPrecise, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.

Dr. Shuji Sato, PHD, Vice President of Innovative Solutions

Shuji Sato serves as the Vice President of Innovative Solutions for IPA with a focus on consistently delivering high value, technologically advanced scientific services to meet the objectives of the most challenging projects. He has over 20 years of experience in various R&D settings, including directing in vivo and in vitro antibody discovery and development teams at numerous biotech and pharma as well as in academia. He applies his broad knowledge in drug development to conceptualization and realization of projects and drives development of effective and innovative workflows.  

Dr. Sato holds a PhD in Molecular Microbiology from Tufts University and trained as a postdoctoral fellow at Harvard Medical School, prior to joining Cell Signaling Technology’s innovative research group and has held Principal Scientist and Associate Director positions at Bluefin Biomedicine, Pfizer and Dragonfly Therapeutics. Throughout his research career, Dr. Sato has co-authored numerous peer-reviewed scientific articles and patents. 

 

Lori Anderson Lori Anderson, Vice President of Brand Marketing and Creative

Lori Anderson is the Vice President of Brand Marketing and Creative at IPA, where she leads brand development and strategy, marketing, and creative direction across IPA’s global portfolio. With over 20 years of experience, Lori has built a career transforming medtech and healthcare brands, from startups to Fortune 5 companies. Her expertise spans brand vision, campaign development, and market expansion, shaped by roles on both the agency and client sides.

Before joining IPA, Lori held senior creative leadership roles, including Executive Creative Director at a leading branding agency and Senior Director of Brand at Optum. She holds a Bachelor of Fine Arts in Design and has earned national recognition for her work in brand identity and integrated omni campaign development.

 
 
ImmunoPrecise Antibodies Ltd.

Follow us

  • follow us on twitter
  • follow us on linkedin
  • follow us on facebook

IR Contact

investors@ipatherapeutics.com

Main Website

https://www.ipatherapeutics.com/

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At ImmunoPrecise Antibodies Ltd., we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to ImmunoPrecise Antibodies Ltd. to send you the requested Investor Email Alert updates.

* Required

*
Investor Alert Options
*





Unsubscribe

Email Alert Sign Up Confirmation

Request a meeting with management
  • Privacy Policy
  • Cookies Policy
  • Terms of Use
©2023 ImmunoPrecise Antibodies LTD. All rights reserved. IPA is a trademark of ImmunoPrecise Antibodies LTD.
Powered By Q4 Inc. 5.157.0.3 (opens in new window)